Skip to content

Free cash flow at other companies

Celcuity logo
CelcuityCELC
-$55.31M-54.0%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-$355.7M-79.9%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$48.46M+289%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$87.33M-30.2%
Tango Therapeutics logo
Tango TherapeuticsTNGX
-$44.36M-6.3%
LQD
Liquidia CorporationLQDA
$50.16M+262%

Other financials

Income statement

See full
Revenue$3.0M-60.9%
Operating income-$78.6M+7.4%
Net income-$73.3M+4.9%
EPS (diluted)-$0.41+10.9%

Balance sheet

See full
Cash & equivalents$204.6M+119%
Total debt$31.6M-33.1%
Total equity$642.2M-10.9%
Total assets$699.6M-12.5%

Cash flow

See full
Operating cash flow-$51.1M+30.2%
CapEx$1.0K

Valuation

See full
Market cap$3.46B+300%
Enterprise value$3.29B+304%
P/S324.1×+212×

Profitability

See full
Operating margin-2,776.6%-820pp
Net margin-2,554.1%-745pp
FCF margin-1,536%-429pp

Returns & leverage

See full
Return on equity-40%-4.3pp
Debt / equity0.0×
Current ratio22.1×+2.2×

Where this comes from

Calculated from Relay Therapeutics, Inc.’s reported figures.

The official record: Relay Therapeutics, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relay Therapeutics, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relay Therapeutics, Inc.'s free cash flow?
Relay Therapeutics, Inc. (RLAY) reported free cash flow of -$44.87M in Q4 2025.
How has Relay Therapeutics, Inc.'s free cash flow changed year-over-year?
Relay Therapeutics, Inc.'s free cash flow increased by 22.5% year-over-year, from -$57.87M to -$44.87M.
What is the long-term trend for Relay Therapeutics, Inc.'s free cash flow?
Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s free cash flow has grown at a 31.9% compound annual growth rate (CAGR), from -$77.88M to -$235.87M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.